

**IN THE CLAIMS:**

Amend the claims as follows:

1. (Original) An aggregated composition comprising (a) a sub-fragment of the 159-301 fragment of full length VP22 protein, and (b) an oligonucleotide or polynucleotide.
2. (Original) An aggregated composition according to claim 1, which further comprises a pharmaceutically acceptable excipient.
3. (Original) An aggregated composition according to claim 1, wherein the sub-fragment is a VP22 fragment selected from the group consisting of: fragments comprising amino acid residues of either (a) 194-226 of full length VP22, or (b) 191-220 of full length VP22, or (c) 191-226 of full length VP22.
4. (Previously Presented) An aggregated composition according to claim 1, wherein the sub-fragment of VP22 is labelled.
5. (Currently Amended) An aggregated composition according to claim 4, wherein the sub-fragment is either VP22 peptide 194-226KRRRR (SEQ ID NO:1) labelled at the C terminal end of VP22, or VP22 peptide 194-226K labelled at the C terminal end of VP22.
6. (Previously Presented) An aggregated composition according to claim 1, wherein the sub-fragment of VP22 is modified by deletion or substitution.

7. (Previously Presented) An aggregated composition according to claim 1, wherein the sub-fragment of VP22 is a fusion protein which also comprises a non-VP22 polypeptide sequence.

8. (Previously Presented) A method of making an aggregated composition according to claim 1 comprising (a) mixing the sub-fragment of VP22 with the oligonucleotide or polynucleotide, and (b) allowing the mixture obtained in step (a) to form aggregates, e.g. aggregates with a particle size of about 0.1 to about 5 microns, e.g. about 1 to about 3 microns, e.g. by incubating the mixture at about room temperature for at least about 10 minutes.

9. (Previously Presented) Use of an aggregated composition according to claim 1 in the manufacture of a medicament for the purpose of therapy or prophylaxis of disease.

10. (Previously Presented) Use of an aggregated composition according to claim 1 in the manufacture of a medicament to deliver desired molecules to cells in vivo.

11. (Previously Presented) Use of an aggregated composition according to claim 1 in to deliver desired molecules to cells in vitro.

12. (Previously Presented) A combined preparation comprising (a) an aggregated composition according to claim 1, and (b) a disaggregating agent for administration separately or sequentially for use in therapy to treat disease or for use prophylactically to stimulate an immune response or to deliver desired molecules to cells, e.g. in vivo or in vitro